Merck And Cie Kmg
Switzerland Updated 9 July 2026
Merck And Cie Kmg is an API manufacturer based in Switzerland. It holds 3 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 29 March 2023 as VAI.
3
registered plants
2 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 29 March 2023 VAI US FDA
- 10 May 2019 NAI US FDA
- 2 November 2018 VAI US FDA
- 12 June 2014 NAI US FDA
- 14 February 2014 NAI US FDA
- 27 July 2011 NAI US FDA
- 25 March 2010 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Schaffhausen, Switzerland | Not on file |
| Switzerland, Switzerland | 3002806918 |
| Switzerland, Switzerland | 3004369363 |
What they file, and where
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| EMA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Merck And Cie Kmg comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 29 March 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates